Polynucleotides and polypeptide sequences involved in cancer

Abstract

The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.

1 - 93 . (canceled) 
     
     
         94 . An isolated or purified antibody or an antigen-binding fragment thereof capable of specifically binding to a polypeptide selected from the group consisting of;
 a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO.:70 (KAAG1), and;   b) a polypeptide comprising a sequence encoded by SEQ ID NO.:24 or a fragment of at least 6 amino acids of said polypeptide.   
     
     
         95 - 96 . (canceled) 
     
     
         97 . An hybridoma cell producing the antibody or antigen binding fragment thereof of  claim 94 . 
     
     
         98 - 99 . (canceled) 
     
     
         100 . A composition comprising the antibody or antigen binding fragment thereof of  claim 94 . 
     
     
         101 . A method of making an antibody comprising immunizing a non-human animal with an immunogenic fragment of a polypeptide selected from the group consisting of
 a. a polypeptide comprising the amino acid sequence set forth in SEQ ID NO.:70 (KAAG1), and;   b. a polypeptide comprising a sequence encoded by SEQ ID NO.:24.   
     
     
         102 - 124 . (canceled) 
     
     
         125 . A method of treating cancer comprising administering an antibody or an antigen binding fragment thereof capable of specific binding to a polypeptide selected from the group consisting of
 a. a polypeptide comprising the amino acid sequence set forth in SEQ ID NO.:70 (KAAG1)   b. a polypeptide encoded by SEQ ID NO.:24,   c. a fragment of any one of a) or b),   d. a derivative of any one of a) or b) and;   e. an analog of any one of a) or b).   
       to a mammal in need. 
     
     
         126 . (canceled) 
     
     
         127 . The antibody or antigen binding fragment thereof of  claim 94 , wherein the antibody or antigen binding fragment thereof is linked to a toxin. 
     
     
         128 . The composition of  claim 100 , wherein the antibody or antigen binding fragment thereof is linked to a toxin. 
     
     
         129 . A method of treating cancer, the method comprising administering a toxin-linked antibody or antigen binding fragment thereof that specifically binds to a polypeptide having the amino acid sequence set forth in SEQ ID NO.:70 (KAAG1) to a cancer patient having a) ovarian cancer, prostate cancer, renal cancer, lung cancer, colon cancer, breast cancer, central nervous system cancer, leukemia or melanoma comprising cancer cells expressing the polypeptide and b) normal kidney cells that do not express KAAG1, wherein the toxin-linked antibody or antigen binding fragment thereof comprises complementarity determining regions identical to those of a monoclonal antibody, chimeric antibody, humanized antibody, human antibody or of a Fab fragment thereof that specifically binds to the polypeptide and wherein the toxin is toxic to the cancer cells. 
     
     
         130 . The method of  claim 129 , wherein the cancer patient is selected prior to administration for having a) ovarian cancer, prostate cancer, renal cancer, lung cancer, colon cancer, breast cancer, central nervous system cancer, leukemia or melanoma comprising cancer cells expressing a polypeptide having the amino acid sequence set forth in SEQ ID NO.:70 (KAAG1) and b) normal kidney cells that do not express KAAG1. 
     
     
         131 . The method of  claim 129 , wherein the method is for treating ovarian cancer in a cancer patient suffering from ovarian cancer. 
     
     
         132 . The method of  claim 131 , wherein the ovarian cancer is late stage ovarian cancer. 
     
     
         133 . A method of inhibiting the growth or survival of cancer cells, the method comprising administering a toxin-linked antibody or antigen binding fragment thereof that specifically binds to a polypeptide having the amino acid sequence set forth in SEQ ID NO.:70 (KAAG1) to a cancer patient having a) a cancer comprising cancer cells expressing the polypeptide and b) normal kidney cells that do not express KAAG1, wherein the toxin-linked antibody or antigen binding fragment thereof comprises complementarity determining regions identical to those of a monoclonal antibody, chimeric antibody, humanized antibody, human antibody or of a Fab fragment thereof that specifically binds to the polypeptide and wherein the toxin is toxic to the cancer cells.